Background In the randomized Global Utilization of t-PA and Streptokinase for Occluded
Coronary Arteries (GUSTO-I) trial, 41 021 patients received one of four thrombolytic …

Numerous controlled clinical trials have documented the efficacy of thrombolytic agents in
reducing the risk of mortality after myocardial infarction (MI). As a result, it is no longer ethical …

Background—Early reinfarction after thrombolytic therapy is associated with adverse
outcomes and increased mortality. Among patients with reinfarction in the 1992 Global …

Thrombolytic therapy remains a mainstay for the treatment of patients with acute myocardial
infarction. This therapy has been the subject of intense investigation and multiple studies as …

Several modes of reperfusion therapy for evolving myocardial infarction (MI) have been
developed, which differ in terms of effectiveness, complexity and costs. Reperfusion …

Thrombolytic therapy for the removal of intravascular thrombi was introduced when
streptokinase was first given to humans 40 years ago, the same year the American College …

The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded
Coronary Arteries (GUSTO) trial, a recent randomized “megatrial” of thrombolytic therapies …

Abstract The Global Utilization of Streptokinase and Tissue Plasminogen Activator for
Occluded Coronary Arteries (GUSTO) trial is a large scale international trial of new …

The causative role of coronarv artery thrombosis in acute transmural myocardial infarction is
well estab-lished [1, 2]. Rupture of atheromatous plaque leads to occlusive thrombosis …

Based on apparent higher recanalization rates of the infarct-related artery, preferential use
of thrombolytic agents with high clot specificity has been proposed for treating patients with …